Dementia

The drug’s developer announced that the FDA has made 2 clarifying revisions.

What is new in research on psychiatric care for Latinx patient populations?

What is new in research on attention-deficit/hyperactivity disorder?

From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.

“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”

Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.

"There is clearly a large unmet need not only to improve our treatment of AD, but to provide treatment options for all the dementias."

From the FDA traditional approval of Leqembi to an examination of how we can improve mental health care for women of color, here are highlights from the week in Psychiatric Times.

Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.

From substance use among adolescents and young adults to managing behavioral and psychological symptoms of dementia, here are highlights from the week in Psychiatric Times.

Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.

From connections between bvFTD and primary psychiatric disorders to the impact of posttraumatic neuroendocrine dysfunction on recovery, here are highlights from the week in Psychiatric Times.

In this CME, learn more about frontotemporal lobar degeneration and the several overlapping syndromes that it encompasses, as well as how to distinguish behavioral variant frontotemporal lobar degeneration from other psychiatric disorders.

From eating disorders in entertainment to early intervention for schizophrenia, here are highlights from the week in Psychiatric Times.

If approved, the drug will be the first FDA-approved treatment for agitation associated with Alzheimer dementia in the United States.

"It is amazing how much we know about the magnificent brain—and how much we have yet to learn."

The experts weighed in on a wide variety of psychiatric issues for the March 2023 issue of Psychiatric Times.

In this CME, learn the current criteria, unique diagnostic biomarkers, and differential diagnosis of Lewy body dementia.

From Alzheimer disease treatments to the psychiatric implications of conspiracy theories, here are highlights from the week in Psychiatric Times.

A look at one of the most informative yet easy-to-administer tests for assessing brain dysfunction.

Researchers performed a nationwide register-based cohort study of patients treated with lithium in Finland.

Lithium: what’s its history and where do we still need more information?

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

"Dementia is a mental health condition that can make or break families. Remember that behind the difficult behavior is your loved one."

What's the latest in dementia?

"To be sure, we are still in the nascent stages of developing treatments. However, our armamentarium is steadily growing."

From the cross-cultural dimensions of psychosis to the economic burden of schizophrenia, here are highlights from the week in Psychiatric Times.

Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.